Indapta Therapeutics
PrivateLast Round
VC Round
Dec 17, 2024
Total Funding Raised
$54.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Indapta Therapeutics is a biotechnology company developing a proprietary, off-the-shelf, allogeneic FcRγ-deficient natural killer (g-NK) cell therapy platform to treat cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Indapta Therapeutics Comparables
Compare Indapta Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Artiva | 87% | |
| Wugen | 86% | |
| CytoImmune Therapeutics | 85% |
Indapta Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Dec 17, 2024 | ||||
| Grant | May 15, 2024 | ||||
| Series A | Feb 10, 2022 |
Key People
Founding team and executive leadership
Indapta Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cancer Prevention & Research Institute of Texas | Grant |
| RA Capital Management | VC Round, Series A |
| Vertex Ventures HC | VC Round, Series A |
| Pontifax Venture Capital | VC Round |
| Pontifax Credit | VC Round |
| Cancer Prevention and Research Institute of Texas | Grant |
| Leaps by Bayer | VC Round, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 116% MoM.
- Jul 26, 2026
Monthly visitors increased 37% MoM.
Indapta Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Indapta Therapeutics's valuation, stock price, and market status.
Is Indapta Therapeutics a public or private company?
Indapta Therapeutics is a private company.
What is the current stock price of Indapta Therapeutics?
Indapta Therapeutics is a private company, so its shares have no public market price. Caplight tracks Indapta Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Indapta Therapeutics worth (valuation)?
Valuation information for Indapta Therapeutics is not publicly available.
Can I buy Indapta Therapeutics stock?
Indapta Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Indapta Therapeutics's last funding round?
Indapta Therapeutics's most recent funding round was VC Round on December 17, 2024.
Who are the main investors in Indapta Therapeutics?
Key investors in Indapta Therapeutics include Cancer Prevention & Research Institute of Texas, RA Capital Management, Vertex Ventures HC, Cancer Prevention and Research Institute of Texas, Leaps by Bayer.
Will Indapta Therapeutics IPO soon?
No public IPO plans have been announced for Indapta Therapeutics.
How can I track Indapta Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Indapta Therapeutics's shares on secondary markets.